Dr. Xianbin Yang
University of Houston at Clear Lake, USA, Email: [email protected]
Xianbin Yang, Ph.D & MBA, currently serves as the Director of Research and Development for AM Biotechnologies. He has over 20 years of experience of working in academic and biotechnology industry on various aspects of nucleic acid chemistry, drug development, and practical applications of nucleic acid technologies, including RNAi, anti-miRNA and Aptamers. Dr. Yang has managed several multimillion dollar-projects, as well as numerous collaboration projects with various institutes and universities. He was the PI for 12 competitive awarded grants: 7 from the National Institute of Health (NIH), 3 from the National Aeronautics and Space Administration (NASA), 1 from the National Natural Science Foundation, and 1 from the Mike Hogg Foundation. One of his NIH proposals was awarded $1M in funding with the highest score possible (scored 10). In 2003, Dr. Yang was awarded the James W. McLaughlin Bronze Medal for Research Excellence in Infection and Immunity from the University of Texas Medical Branch (UTMB). In 2012, Dr. Yang became the first recipient of the Young Investigator Award from the Oligonucleotide Therapeutics Society. Prior to AM Biotechnologies, Dr. Yang worked as the Manager of Research and Development at AptaMed from 2002 to 2006. He was responsible for generating thioaptamer candidates for a number of different infectious diseases targeting for both diagnostics and therapeutics. He was a faculty member at UTMB from 2004 to 2007 and was also appointed as adjunct faculty or Professor from several other universities. Dr. Yang is an inventor with 4 awarded patents and 5 pending patents. He is an author/co-author for 65 publications and two book chapters. He was invited to give over 65 presentations at institutes and international meetings all over the world during the last 10 years. He was also invited to review NIH RO1 grants and several international journals. Dr. Yang obtained his Ph.D from the Polish Academy of Sciences in Poland, followed by a postdoctoral fellow position supported by NIH at UTMB. He received his MBA from the University of Houston at Clear Lake in 2010 and has also earned his bachelor and master?s degrees from Peking University.
My interests primarily center around the nucleic acid chemistry & biochemistry, molecular biophyscis, combinatorial chemistry, X-ray crystal structure and NMR spectroscopy working in the areas of drugs development, protein and nucleic acid interactions, and recognition.